Patient organisation-led initiatives can play an important role in raising awareness about Raynaud’s phenomenon and encourage earlier healthcare utilisation for high-risk groups

Raynaud’s phenomenon (RP) manifests as episodic vasospasm of the extremities (hands and feet) in response to cold exposure. RP can be primary (idiopathic) or secondary to underlying disease such as systemic sclerosis (SSc). Attacks of RP are often associated with digital colour changes reflecting local tissue perfusion and oxygenation. RP results in pain, numbness, impaired function and reduced quality of life. The obliterator vasculopathy of SSc can result in digital ulceration. Diagnostic delay of secondary RP remains a major unmet need. The time between the onset of RP and emergence of the first non-RP symptom can be over 5 years. This contributes to delay in diagnosis; with >25% of women not diagnosed with SSc for 10 years after the be over 5 years.3 This contributes to delay in diagnosis; with >25% of women not diagnosed with SSc for 10 years after the emergence of RP.

Against this background, Scleroderma Raynaud’s UK (SRUK) led an initiative to devise a ‘Raynaud’s test’ for visitors to their website (https://www.sr.uk.co.uk/raynauds/raynauds-test/). The test, developed by SRUK and RP experts, comprises questions derived from existing RP classification criteria1,2 to determine if RP is likely and whether further assessment is necessary (table 1). No identifiable information is collected. Algorithms provide respondents with statements indicating ‘This is unlikely to be Raynaud’s’ or that ‘You may have Raynaud’s’. Participants are encouraged to seek medical advice if they experience painful or frequent symptoms, or have other concerns. All participants answering ‘yes’ to question 5 (irrespective of other responses) are given recommendations to seek assessment in primary care (table 1).

We examined anonymised data from 18 840 respondents from 43 countries who completed the ‘Raynaud’s test’ between 22/06/2017 and 21/06/2018. We have no information on who completed the test or how they acted on the information supplied in response to their answers. The figures are solely presented to provide some impression of the possible demographics of those completing the test. RP was deemed ‘unlikely’ in 1138 (6%). The majority of respondents were informed they ‘may have Raynaud’s’ (14140, 75%). The remaining 3562 respondents (19%) were also informed that they may have Raynaud’s, but given additional advice to seek medical attention having reported the development of digital ischaemic lesions (yes to question 5). Accepting the inevitable selection bias accompanying positioning the test on the SRUK website, the considerable proportion of respondents reporting features that might represent secondary RP was of interest and, it is hoped, may have encouraged some respondents to seek medical attention when they had not previously done so.

Utilisation of our Raynaud’s test highlights the large number of people visiting patient organisation websites for information and the potential of patient organisations to encourage involvement of people in their own healthcare. Our findings also highlight the global reach of ‘National’ web-based patient organisations. The internet has provided the general public with a readily

| Table 1 The questions and responses comprising the online SRUK ‘Raynaud’s Test’ |
|---------------------------------|-----------------|---------------------------------|
| **Questions (Q) comprising the Raynaud’s Test** | **Responses provided to visitors depending on their answers to questions 1–5** |
| Question 1 Are your fingers sensitive to the cold? | No to Q1 OR Q2-5 | This is unlikely to be Raynaud’s, however if you experience painful or frequent symptoms, or are concerned, then it may be worthwhile visiting a GP. You may be oversensitive to the cold and so to reduce your symptoms try to keep warm. Take a look at our information below to support you with keeping warm and avoiding smoking. If you would like to know more information about Raynaud’s then why not have a look at the further information below. Raynaud’s is a common condition affecting around 1 in 6 people. Raynaud’s symptoms generally affect the fingers and toes, but all extremities can be involved, including the ears. |
| Question 2 Do your fingers change colour in response to temperature change or stressful situations? (white, blue, red and purple) | Yes to Q1 but no to Q2-5 | You may have Raynaud’s Raynaud’s is a common condition affecting around 1 in 6 people. In people who have Raynaud’s, the small blood vessels in the extremities are oversensitive to changes in temperature or stress causing a Raynaud’s attack. Raynaud’s symptoms generally affect the fingers and toes, but all extremities can be involved, including the ears, nose, lips, tongue and nipples. If you are experiencing painful or frequent symptoms then it is worthwhile visiting your GP to discuss the situation, including management techniques and possible treatment options. |
| Question 3 Do you get numbness or pain in the affected area when they change colour? | Yes to Q1, Yes to one of Q2-4, and No to Q5 | You may have Raynaud’s Raynaud’s is a common condition affecting around 1 in 6 people. In people who have Raynaud’s, the small blood vessels in the extremities are oversensitive to changes in temperature or stress. This causes a Raynaud’s attack where the fingers change colour typically white, blue or red. Raynaud’s symptoms generally affect the fingers and toes, but all extremities can be involved, including the ears, nose, lips, tongue and nipples. If you are experiencing painful or frequent symptoms then it is worthwhile visiting your GP to discuss the situation, including management techniques and possible treatment options. |
| Question 4 Do you feel stinging or throbbing when the affected area warms up? | Yes to Q5, irrespective of the answers provided to Q1-4 | You may have Raynaud’s Raynaud’s is a common condition affecting around 1 in 6 people. In people who have Raynaud’s, the small blood vessels in the extremities are oversensitive to changes in temperature or stress. This causes a Raynaud’s attack where the fingers change colour typically white, blue or red. Raynaud’s symptoms generally affect the fingers and toes, but all extremities can be involved, including the ears, nose, lips, tongue and nipples. The majority of people with Raynaud’s symptoms have ‘Primary Raynaud’s phenomenon’ which can be intrusive but should not cause any lasting damage to the fingers. Primary Raynaud’s often starts during adolescence. A minority of people experiencing Raynaud’s have an underlying health condition causing these symptoms. We use the term ‘Secondary Raynaud’s phenomenon’ when this is the case. This can be more serious, and we have tests available to help identify people who might have secondary Raynaud’s. If you have developed sores or ulcers on your fingers or toes then we would recommend an assessment at your GP surgery to rule out an underlying health problem. |
| Question 5 Have you ever developed any sores/ulcers on your fingers or toes? | |

GP, general practitioner; SRUK, Scleroderma Raynaud’s UK.
available tool for the self-investigation of new experiences/symptoms that might indicate the presence of disease. Carefully designed tools of this nature can positively influence health utilisation by providing reassurance to people interested to learn about RP and encouraging earlier medical assessment of people at risk of potentially life-threatening disease such as SSc. Collaboration between healthcare professionals, patient organisations and the public is at the heart of important initiatives such as the European League Against Rheumatism ‘Don’t Delay, Connect Today!’ campaign, that is seeking to raise awareness around the importance of early diagnosis. The diagnostic potential of mobile health technology is fast becoming an important tool for influencing patient referral processes and can be particularly valuable for people living in remote areas. We must, however, be alert to the dangers of diagnostic inaccuracy and incorporate appropriate safeguards that ensures timely secondary care assessment using diagnostic tools such as nailfold videocapillaroscopy in high-risk patients.8 9

Michael Hughes,1,2 Amy Baker,3 Sue Farrington,3 John D Pauling4,5
1Department of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
2Centre for Musculoskeletal Research, The University of Manchester, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
3Scleroderma and Raynaud’s UK, London, UK
4Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), Bath, UK
5Department of Pharmacy and Pharmacology, University of Bath, Bath, UK

Correspondence to Dr John D Pauling, Royal National Hospital for Rheumatic Diseases, Bath, BA1 1RL, UK; johnpauling@nhs.net

Handling editor Josef S Smolen

Acknowledgements The authors wish to thank Professor Ariane Herrick for her help devising questions and responses comprising the ‘Raynaud’s Test’.

Contributors All authors were involved in the planning, conduct and reporting of the work described in the article.

Funding This study was funded by Scleroderma and Raynaud’s UK.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.


Received 21 July 2018
Revised 13 September 2018
Accepted 13 September 2018


REFERENCES